Pharmaceutical manufacturers are investing heavily in contract development and manufacturing organization (CDMO) partnerships to clear persistent supply bottlenecks for metabolic therapeutics.
Fill-Finish Constraints
While active pharmaceutical ingredient (API) synthesis capacity has expanded by 40%, specialized sterile injector fill-finish lines remain capped, limiting final market delivery.
Capital Reallocation
Major drugmakers have committed $8.5 billion to dedicated internal sterile assembly facilities, though operational output is not projected to balance market demand until late next year.